noom.semaglutide Why We Launched Noom GLP-1RX Introducing Noom GLP-1ᴿˣ — trusted

Despite lower efficacy and tolerability shown by nasally administered PYY agonists in early studies, long-acting subcutaneous PYY receptor agonists such as PYY 1875 are undergoing early-phase clinical trials to evaluate their safety and effectiveness as monotherapy or in combination with GLP-1 receptor agonists for the treatment of obesity

Nearly half of Americans are living with obesity, which is associated with more than 200 related health issues and diseases, including type 2 diabetes

doi:10.2337/diabetes.53.8.2079 110

Mascitelli L, Pezzetta F, Sullivan JL

Depending on your individual needs, your provider may recommend ongoing injections or transition you to a different regimen once your levels are stable